GlassScriptPhysician profile
Haresh D Patel
NPI 1104115187
$3,070.60
in general payments reported to CMS, 2019-2025
24 companies · $378 in 2025
The $378 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $711 · 2020: $260 · 2021: $178 · 2022: $73.63 · 2023: $1,070 · 2024: $399 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,847.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,265.64 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Regeneron Healthcare Solutions, INC. | $415.58 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $257.19 | 2019-2023 | Xolair |
| Glaxosmithkline, LLC. | $224.44 | 2019-2023 | Nucala |
| Medical Device Business Services, INC. | $112.21 | 2023 | |
| Baxter Healthcare | $105.71 | 2023 | Hillrom - Life 2000 Ventilation System |
| Novartis Pharmaceuticals Corporation | $93.10 | 2019-2023 | |
| Genzyme Corporation | $71.16 | 2019-2023 | |
| Electromed, INC. | $65.55 | 2019-2023 | Smartvest |
| Advanced Respiratory, INC | $61.97 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $54.88 | 2023 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $48.84 | 2023 | Glassia |
| Philips North America LLC | $43.91 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.66 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Penumbra, INC. | $39.22 | 2023 | Indigo System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $26.87 | 2024 | Tezspire |
| Mylan Specialty L.P. | $22.77 | 2023 | Yupelri |
| Allergan, INC. | $21.73 | 2019 | |
| Shire North American Group INC | $19.44 | 2019 | |
| Resmed Corp | $17.51 | 2020 | |
| United Therapeutics Corporation | $15.48 | 2025 | Tyvaso |
| Astellas Pharma US INC | $15.36 | 2019 | |
| Circassia INC. | $14.58 | 2019 | |
| Jazz Pharmaceuticals INC. | $13.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haresh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.